Compare TLSA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLSA | HUMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 165.7M |
| IPO Year | 2017 | 2020 |
| Metric | TLSA | HUMA |
|---|---|---|
| Price | $0.68 | $0.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $7.87 | $1.64 |
| AVG Volume (30 Days) | 522.3K | ★ 4.4M |
| Earning Date | 05-01-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $98.07 |
| Revenue Next Year | N/A | $480.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.34 |
| 52 Week High | $1.90 | $1.53 |
| Indicator | TLSA | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 54.36 |
| Support Level | $0.57 | $0.36 |
| Resistance Level | $1.21 | $0.62 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.24 | 56.57 |
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.